Background {#Sec1}
==========

Succinylcholine, also known as suxamethonium, has been introduced into anaesthesia practice in the early 1950s \[[@CR1]\]. Still today, it remains one of the most commonly used neuromuscular blocking agents for rapid sequence induction (RSI) because of its fast onset and short duration of action \[[@CR2]\]. The "cannot intubate, cannot ventilate" scenario is a threat of airway management. Therefore, clinicians are inclined to administer the minimally effective dose of succinylcholine that is meant to provide excellent intubating conditions but that provokes only a short apnoea time. The widely recommended standard intubating regimen of succinylcholine has been 1.0 mg kg^− 1^, although the scientific basis of that specific regimen remains unclear \[[@CR3]\]. Indeed, a dose of 1.0 mg kg^− 1^ corresponds to almost four times the ED95, which is unusual for a neuromuscular blocking agent \[[@CR4], [@CR5]\].

We performed a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the optimal regimen of succinylcholine for RSI. In this context, the optimal regimen was defined as the mg per kg bodyweight regimen that provided the highest likelihood of excellent intubating conditions, the lowest risk of unacceptable intubating conditions, and the shortest apnoea time compared with the gold standard regimen. As 1.0 mg kg^− 1^ has been reported to be the gold standard in this context \[[@CR3]\], we compared all alternative, experimental regimens with that gold standard regimen.

Methods {#Sec2}
=======

We performed a quantitative systematic review following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and according to Cochrane methodology \[[@CR6], [@CR7]\]. A PRISMA checklist is available as a supplement (Table [S1](#MOESM1){ref-type="media"}).

Systematic search and study selection {#Sec3}
-------------------------------------

Two authors (MG, AP) searched three electronic databases (PubMed, CENTRAL, EMBASE) from inception to 15 February 2019 using a variety of high-sensitivity and low-specificity search strategies. Details of the search strategy for PubMed are available as a supplement (Methods [S1](#MOESM1){ref-type="media"}). There was no language restriction. Reference lists of retrieved articles were checked for further potentially relevant publications (backward snowballing). Retrieved articles were screened by three authors (CC, AP, MG). Discrepancies and queries for inclusion were resolved through consensus. If agreement could not be reached, discrepancies were discussed with the fourth author (MRT).

Inclusion and non-inclusion criteria {#Sec4}
------------------------------------

We included full reports of RCTs performed in adults (≥18 years) undergoing surgery that compared any experimental regimen of succinylcholine with the standard regimen, 1.0 mg kg^− 1^, for RSI. We included studies that tested a 'true' or a 'modified' RSI procedure \[[@CR8]\]. A true procedure involves intravenous induction with a hypnotic, intravenous administration of succinylcholine immediately (i.e. without any delay) after loss of consciousness, an apnoea period of no more than 60 s followed by orotracheal intubation. A modified RSI procedure is different in that the delay between loss of consciousness and the administration of the neuromuscular blocking agent is longer and allows, for instance, the additional recording of electromyographic baseline measures. During this time period, the patient is usually ventilated and oxygenated through a facemask. However, as with true RSI, after administration of the neuromuscular blocking agent, the apnoea period before orotracheal intubation is lasting no longer than 60 s.

Eligible trials had to report on intubating conditions using a validated score that evaluated ease of laryngoscopy, vocal cord position and movement, airway reaction, and movement of limbs \[[@CR9]\]. We did not consider studies including obese patients for two reasons. Firstly, obesity is an independent risk factor of difficult laryngoscopy and tracheal intubation \[[@CR10]--[@CR12]\]. Secondly, the best succinylcholine regimen in obese patients remains controversial \[[@CR13], [@CR14]\]. Data from non-randomized trials, paediatric studies, abstracts, and trials that lacked a succinylcholine 1.0 mg kg^− 1^ group were also not taken into account.

Data extraction {#Sec5}
---------------

Two authors (MG, CC) read the full-text articles, extracted independently all relevant information and entered the data into a predefined electronic form. Discrepancies were resolved by discussion with a third author (MRT).

Outcomes {#Sec6}
--------

According to good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents \[[@CR9]\], excellent, good or unacceptable intubating conditions may be distinguished. Excellent intubating conditions are present when all variables of the intubating score (ease of laryngoscopy, vocal cord position and movement, airway reaction, movement of limbs) are rated as excellent. Unacceptable intubating conditions are present when at least one variable of the intubating score is rated as poor. We chose the incidence of excellent intubating conditions (evaluated 50 to 60 s after the administration of succinylcholine) as the primary outcome as we regarded this outcome as the clinically most relevant in the context of RSI. The incidence of unacceptable intubating conditions was regarded as a secondary outcome. Good intubating conditions were not further analysed as we did not expect these data to inform decision-making. A further secondary outcome was apnoea time. Two definitions of apnoea time were used in the retrieved trials. First, apnoea time was defined as the time in minutes from succinylcholine administration to the occurrence of the first visible diaphragmatic contractions that coincided with movements of the reservoir bag. It was shown that this definition correlated with the incidence of haemoglobin desaturation defined by an oxygen saturation less than 80% \[[@CR15]\]. Second, in some trials, apnoea time was defined as obvious recognizable end-tidal CO~2~ waveforms appearing on the monitor.

Risk of Bias in individual studies {#Sec7}
----------------------------------

Quality of data reporting was assessed by two authors (MG, CC) and independently checked by another author (AP) using the Cochrane Collaboration method \[[@CR7]\] and a modified 4-item, 7-point Oxford scale taking into account the method of randomization, concealment of treatment allocation, degree of blinding, and reporting of drop-outs, as previously described \[[@CR16]\]. In the case of divergence of opinion, consensus was reached by discussion with the fourth author (MRT).

Statistical analyses {#Sec8}
--------------------

Many comparisons contained zero cells, which made the calculation of risk ratios impossible. In order not to lose potentially relevant information, we decided to calculate absolute risk differences (ARD) with 95% confidence intervals (CI) for dichotomous data. When the 95% CI around the ARD did not cross 0, the result was considered statistically significant (*p* value equal or inferior to 0.05). We also computed numbers needed to treat (NNT) with 95% CI as the inverse of the ARD point estimates and the lower and upper limits of their 95% CI. The NNT was the estimated number of patients who needed to be treated with the experimental regimen for one additional patient to have one more outcome compared with the comparator. A positive ARD suggested that an outcome was improved with an experimental regimen compared with the standard regimen and was consequently translated into a positive NNT. A negative ARD suggested that an outcome was worsened with an experimental regimen compared with the standard regimen and was consequently translated into a negative NNT (which may then be interpreted as a "number needed to harm"). An ARD of 0, indicating no difference between the experimental and the standard regimen, was translated into an NNT of infinity (∞). For continuous outcomes, we computed mean differences (MD) with 95% CI. We used a random-effects model throughout (Mantel-Haenszel method). Between studies heterogeneity was quantified using the I^2^ statistics. We performed sensitivity analyses computing relative instead of absolute risk differences and using a fixed-effect instead of a random effects model. Statistical analyses were performed with Review Manager (RevMan \[Computer program\], Version 5.3; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark, 2014) and Microsoft Excel 2010 (for Mac).

Results {#Sec9}
=======

Study selection {#Sec10}
---------------

Our searches yielded 722 potentially relevant reports (Fig. [1](#Fig1){ref-type="fig"}). After exclusion of 690 inappropriate studies, 12 studies were retrieved as complete articles. Of these, six were excluded as they did not meet the inclusion criteria. Two of those tested different doses of succinylcholine without comparison with the gold standard regimen (1 mg kg^− 1^) \[[@CR17], [@CR18]\], two included obese patients only (body mass index ≥40 kg m^− 2^) \[[@CR13], [@CR14]\], and two did not report on intubating conditions \[[@CR19], [@CR20]\]. We finally included six RCTs with relevant data on 864 patients (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR21]--[@CR26]\]. Fig. 1Flow diagram of the study selection process

Study characteristics {#Sec11}
---------------------

Eligible studies were published between 2003 and 2014 (Table [1](#Tab1){ref-type="table"}). They were performed in four countries (China, India, Saudi Arabia, USA) and included between 69 and 200 patients. Patients were ASA 1 or 2, 18 to 65 years old, with a body mass index \< 30 kg m^− 2^. All patients were eligible for elective surgery under general anaesthesia with tracheal intubation, were fasting preoperatively, had no criteria of difficult airway, no contraindication for succinylcholine, and no family history of an abnormal response to succinylcholine. Table 1Characteristics of included trialsTrialCountryExperimental regimens \[mg kg^− 1^\] (number of patients)PMMedications for inductionRapid Sequence InductionCricoid pressureAdverse effectsIntubation failuresEl Orbany 2004USA0.3 (n = 23)0.4 (*n* = 23)0.5 (*n* = 23)0.6 (*n* = 23)1.0 (*n* = 23)YesFentanyl 1.5 μg kg^− 1^Propofol 2 mg kg^− 1^Modifiednrnr7 with succinylcholine 0.3 mg kg^− 1^;2 with succinylcholine 0.4 mg kg^− 1^Luo 2014China0.3 (*n* = 60)0.5 (*n* = 60)1.0 (*n* = 60)NoSevofluraneTrue\*nr"No complications such as cough, laryngospasm, or bronchial spasm attributable to the study"NoneNaguib 2003Saudi Arabia0.3 (*n* = 50)0.5 (*n* = 50)1.0 (*n* = 50)YesFentanyl 2 μg kg^− 1^Propofol 2 mg kg^− 1^Truenr"Each patient was followed up for any adverse affects". Results nr.NoneNaguib 2006USA0.3 (*n* = 30)0.5 (*n* = 30)1.0 (*n* = 30)1.5 (*n* = 30)2.0 (*n* = 30)NoFentanyl 2 μg kg^− 1^Propofol 2 mg kg^− 1^Truenr"Each patient was monitored for any adverse event". Results nr.NonePrakash 2012India0.4 (*n* = 23)0.6 (*n* = 23)1.0 (*n* = 23)NoFentanyl 2 μg kg^− 1^Propofol 2 mg kg^− 1^TrueyesAdverse events were recorded and no episodes of laryngospasm, bronchospasm, masseter spasm, generalized rigidity were observedNoneTaxak 2013India0.4 (*n* = 50)0.6 (*n* = 50)0.8 (*n* = 50)1.0 (*n* = 50)YesMeperidine 1 mg kg^− 1^Propofol 2 mg kg^− 1^Modifiednrnrnr*PM* premedication, *nr* not reported, ^a^true RSI with sevoflurane

All trials included a group with a standard succinylcholine regimen (1.0 mg kg^− 1^). Experimental regimens were 0.3 mg kg^− 1^ \[[@CR21]--[@CR23], [@CR26]\], 0.4 mg kg^− 1^ \[[@CR22], [@CR24], [@CR25]\], 0.5 mg kg^− 1^ \[[@CR21]--[@CR23]\], 0.6 mg kg^− 1^ \[[@CR22], [@CR24]--[@CR26]\], 0.8 mg kg^− 1^ \[[@CR25]\], 1.5 mg kg^− 1^ \[[@CR23]\], and 2.0 mg kg^− 1^ \[[@CR23]\]. Five trials were double blinded. The modified Oxford quality score ranged from 2 to 6. One trial was not blinded and therefore judged to be at high risk of bias (Figure [S1](#MOESM1){ref-type="media"} and [S2](#MOESM1){ref-type="media"}) \[[@CR23]\]. Two trials reported sources of authors' funding and conflicts of interest \[[@CR24], [@CR26]\].

Induction techniques {#Sec12}
--------------------

In three studies, patients were premedicated (Table [1](#Tab1){ref-type="table"}) \[[@CR21], [@CR23], [@CR25]\]. Three studies used a true RSI \[[@CR21], [@CR23], [@CR24]\], and two a modified RSI \[[@CR22], [@CR25]\]. All five used intravenous propofol 2 mg kg^− 1^ with a concomitant intravenous opioid for induction. The sixth study used an induction technique with sevoflurane without intravenous opioids; there was no delay between loss of consciousness and the administration of succinylcholine \[[@CR26]\]. One study specified the use of a cricoid pressure \[[@CR24]\]. In all studies, intubating conditions were evaluated 50 to 60 s after the administration of succinylcholine. Four studies specified that intubations were performed by an experienced anaesthetist \[[@CR21]--[@CR24]\].

Quality of intubating conditions {#Sec13}
--------------------------------

### Excellent intubating conditions {#Sec14}

With the standard succinylcholine regimen (1.0 mg kg^− 1^), the incidence of excellent intubating conditions ranged from 58% \[[@CR26]\] to 100% \[[@CR24], [@CR25]\] (cumulative number of patients, 185 of 233 \[79%\]) (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Excellent intubating conditions with the standard regimen of succinylcholine (1.0 mg kg^− 1^) compared with different experimental regimens. Comparisons are listed according to increasing experimental doses. ARD = absolute risk difference; NNT = number needed to treat; CI = confidence interval; ∞ = infinity (i.e. ARD = 0). A positive ARD suggested that an outcome was improved with an experimental regimen compared with the standard regimen and was consequently translated into a positive NNT. A negative ARD suggested that an outcome was worsened with an experimental regimen compared with the standard regimen and was consequently translated into a negative NNT (which may be interpreted as a "number needed to harm"). An ARD of 0, indicating no difference between the experimental and the standard regimen, was translated into an NNT of infinity (∞)

With four experimental regimens that were tested in at least three trials each (0.3, 0.4, and 0.5 mg kg^− 1^) \[[@CR21]--[@CR26]\], excellent intubating conditions were significantly less frequent compared with 1.0 mg kg^− 1^ (ARD ranging from − 9% to − 67%) (Fig. [2](#Fig2){ref-type="fig"}). With 0.8 mg kg^− 1^, tested in one trial only \[[@CR25]\], excellent intubating conditions were also significantly less frequent compared with 1.0 mg kg^− 1^ (ARD − 12%) (Fig. [2](#Fig2){ref-type="fig"}). With 0.6 and 1.5 mg kg^− 1^, no difference was found. With 2.0 mg kg^− 1^, excellent intubating conditions were significantly more frequent compared with 1.0 mg kg^− 1^ (ARD + 23%) (Fig. [2](#Fig2){ref-type="fig"}). Both 1.5 and 2 mg kg^− 1^ were tested in one trial only \[[@CR23]\]. The I^2^ ranged from 54% to 95% (Figure [S3](#MOESM1){ref-type="media"}).

### Unacceptable intubating conditions {#Sec15}

With the standard succinylcholine regimen (1.0 mg kg^− 1^), the incidence of unacceptable intubating conditions ranged from 0% \[[@CR22], [@CR24], [@CR25]\] to 6.7% \[[@CR26]\] (cumulative number of patients, 6 of 233 \[2.6%\]) (Fig. [3](#Fig3){ref-type="fig"}). With 0.3 and 0.4 mg kg^− 1^, tested in at least three trials each \[[@CR21]--[@CR25]\], unacceptable intubating conditions were significantly more frequent compared with 1.0 mg kg^− 1^ (ARD + 22% and + 32%) (Fig. [3](#Fig3){ref-type="fig"}). With 0.5 and 0.6 mg kg^− 1^, also tested in at least three trials each \[[@CR21]--[@CR25]\], and with 0.8, 1.5 and 2.0 mg kg^− 1^, tested in one trial each \[[@CR23], [@CR25]\], the likelihood of unacceptable intubating conditions was no different from 1.0 mg kg^− 1^ (Fig. [3](#Fig3){ref-type="fig"}). The I^2^ ranged from 0% to 93% (Figure [S4](#MOESM1){ref-type="media"}). Fig. 3Unacceptable intubating conditions with the standard regimen of succinylcholine (1.0 mg kg^− 1^) compared with different experimental regimens. Comparisons are listed according to increasing experimental doses. ARD = absolute risk difference; NNT = number needed to treat; CI = confidence interval; ∞ = infinity (i.e. ARD = 0). A positive ARD suggested that an outcome was improved with an experimental regimen compared with the standard regimen and was consequently translated into a positive NNT. A negative ARD suggested that an outcome was worsened with an experimental regimen compared with the standard regimen and was consequently translated into a negative NNT (which may be interpreted as a "number needed to harm"). An ARD of 0, indicating no difference between the experimental and the standard regimen, was translated into an NNT of infinity (∞)

### Apnoea times {#Sec16}

With the standard succinylcholine regimen (1.0 mg kg^− 1^), average apnoea times, reported in four trials \[[@CR22], [@CR24]--[@CR26]\], ranged from 4.0 min \[[@CR26]\] to 8.2 min \[[@CR24]\] (Fig. [4](#Fig4){ref-type="fig"}). Two experimental regimens, 0.4 and 0.6 mg kg^− 1^, were tested in at least three trials \[[@CR22], [@CR24]--[@CR26]\], and in both, apnoea times were significantly shortened compared with the gold standard regimen (MD, − 3.4 and − 1.9 min, respectively). Three regimens (0.3, 0.5, 0.8 mg kg^− 1^) were tested in one or two trials each \[[@CR22], [@CR25], [@CR26]\] and were associated with shorter apnoea times compared with 1 mg kg^− 1^ (Fig. [4](#Fig4){ref-type="fig"}). With 1.5 and 2.0 mg kg^− 1^, no apnoea times were reported. The I^2^ ranged from 74% to 97% (Figure [S5](#MOESM1){ref-type="media"}). Fig. 4Apnoea times (in min) with the standard regimen of succinylcholine (1.0 mg kg^− 1^) compared with different experimental regimens. The time from injection of succinylcholine until first diaphragmatic movement or until obvious recognizable end-tidal CO2 waveforms appearing on the monitor was used as a surrogate of apnoea time. MD = mean difference; CI = confidence interval; n/a = not applicable (no data reported)

### Sensitivity analyses {#Sec17}

Computing risk ratios did not change the magnitude of the results (Figure [S6](#MOESM1){ref-type="media"}), as did the use of a fixed effect model (Figure [S7](#MOESM1){ref-type="media"}). The exclusion of one trial \[[@CR22]\] decreased the degree of heterogeneity in some analyses but aggregated results remained similar (Figure [S8](#MOESM1){ref-type="media"}).

Discussion {#Sec18}
==========

Main findings {#Sec19}
-------------

We performed a systematic review and meta-analysis of RCTs to evaluate intubating conditions and apnoea times with different succinylcholine regimens. As a gold standard, we have chosen succinylcholine 1.0 mg kg^− 1^, which is probably the most widely used regimen for RSI. We analysed data from six trials including relevant data of 864 patients.

If we consider the outcome "excellent intubating conditions" as the most relevant in the context of RSI (Fig. [2](#Fig2){ref-type="fig"}), we may conclude that regimens equal or lower than 0.5 mg kg^− 1^ produced less often excellent conditions, whereas 2.0 mg kg^− 1^ performed significantly better that 1 mg kg^− 1^. With succinylcholine 2.0 mg kg^− 1^, the number needed to treat suggested that four to five patients needed to be intubated for one to have excellent intubating conditions during RSI who would not have had such excellent conditions had they all received 1 mg kg^− 1^ only. This result must be interpreted cautiously mainly for two reasons. Firstly, 2.0 mg kg^− 1^ was tested in one single trial only with a limited number of patients \[[@CR23]\]. Secondly, in that single trial, only 63% of patients had excellent intubating conditions with the standard regimen, 1.0 mg kg^− 1^ \[[@CR23]\]. This "baseline" incidence was lower compared with the other trials. It can, therefore, not be excluded that 2.0 mg kg^− 1^ performed well since in the only trial that tested this regimen \[[@CR23]\], the gold standard regimen performed relatively badly. Thus, it remains unknown whether 2.0 mg kg^− 1^ further improves "excellent intubating conditions" in a patient population with a high baseline incidence of "excellent intubating conditions".

Alternatively, the outcome "unacceptable intubating conditions" may be regarded as the most relevant in the context of RSI (Fig. [3](#Fig3){ref-type="fig"}). Contrary to the outcome "excellent intubating conditions", the result was much more dichotomous; regimens below 0.5 mg kg^− 1^ were clearly less efficacious compared with the gold standard, 1 mg kg^− 1^, whereas regimens above 0.5 mg kg^− 1^ were no different from 1 mg kg^− 1^. Based on this outcome, it may be deduced that regimens below 0.5 mg kg^− 1^ should be avoided for RSI. Interestingly, with the gold standard regimen 1 mg kg^− 1^, the incidence of "unacceptable intubating conditions" showed much less variability between trials (0% to 6.7%) compared with the outcome "excellent intubating conditions". This suggests that indirect comparisons between different succinylcholine regimens are more reliable when the outcome "unacceptable intubating conditions" is chosen. It also suggests that the outcome "unacceptable intubating conditions" is not ideal to test various degrees of efficacy of experimental regimens compared with the gold standard regimen; with regimens above 0.6 mg kg^− 1^, unacceptable intubating conditions were virtually absent.

Additionally to the outcomes "excellent" and "unacceptable" intubating conditions, apnoea time may be used for rational decision-making (Fig. [4](#Fig4){ref-type="fig"}). With regimens below 0.8 mg kg^− 1^, median apnoea times became constantly shorter, and consequently, mean differences compared with the gold standard regimen increased. There is thus an argument in favour of using lower than standard succinylcholine regimens for RSI. This must however be weighted against the increased risk of having less often excellent intubating conditions and more frequently unacceptable intubating conditions. Data on apnoea times with regimens above 1 mg kg^− 1^ were lacking. Thus, clinically relevant prolongation of apnoea times with 1.5 or 2.0 mg kg^− 1^ needs to be formally shown. Also, the primary factor determining return of spontaneous respiration may not be the depth of neuromuscular block, but the degree of centrally mediated respiratory depression induced by the opioids and hypnotics used for induction of anaesthesia.

Strengths and limitations {#Sec20}
-------------------------

The strength of this meta-analysis is the rigorous systematic review of the literature. Also, we included exclusively RCTs comparing different experimental regimens of succinylcholine with the gold standard regimen, 1 mg kg^− 1^, for RSI and using the same validated intubation score. However, the number of retrieved valid studies was small, the number of included patients limited, and statistical heterogeneity was relatively high. Thus, the evidence base remains weak and the interpretation of the data is not straightforward. Additionally, all trials were performed in low risk patients undergoing elective surgery, although succinylcholine is mainly used for RSI in patients undergoing emergency surgery. Some studies were using a modified RSI technique and in one \[[@CR26]\], sevoflurane was used for induction. This may have introduced clinical heterogeneity. The observed variability of the baseline incidences of excellent intubating conditions suggests that the study populations were not similar or that intubation scores were interpreted differently. Finally, succinylcholine-related adverse effects were not systematically reported and for regimens above 1.0 mg kg^− 1^, data on apnoea times were lacking. For rational decision-making, adverse effects and apnoea times with all tested regimens should be known.

Research agenda {#Sec21}
---------------

It is surprising that efficacy and potential of harm of a drug that has been widely used for almost 60 years in the perioperative setting including anaesthesia, intensive care and emergency medicine, is so poorly documented. This begs the question as to the need for further high quality trials to better understand the role of succinylcholine in patients needing RSI. Specific high-risk patient populations have not be studied, including pregnant women, patients undergoing emergency surgery, and children. Also, the optimal succinylcholine regimen in obese patients remains controversial \[[@CR13], [@CR14]\], and needs further investigation. Trials should report on drug-related adverse effects and apnoea times.

Conclusions {#Sec22}
===========

With succinylcholine regimens ≤0.5 mg kg^− 1^, excellent intubating conditions are less likely compared with the gold standard regimen, 1 mg kg^− 1^. With 0.3 and 0.4 mg kg^− 1^, unacceptable intubating conditions are more common. With regimens below 1 mg kg^− 1^, apnoea times are shorter. With 2 mg kg^− 1^, excellent intubating conditions seem to be more likely but the database is weak, and apnoea times remain unknown. Small information size and strong statistical heterogeneity limit the certainty of the evidence.
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